As previously announced, the product patent for GHRH analogues including tesamorelin, granted on January 19, 1999, expires in 2015. The new patent covering the methods of treatment provides additional patent protection for tesamorelin in HIV-associated lipodystrophy until the year 2023, extending the patent protection for eight additional years.
Yves Rosconi, president and CEO of Theratechnologies, said: “We believe that this will have an impact on the value of Theratechnologies as it will extend the commercial exclusivity in HIV-associated lipodystrophy which is very exciting for us.”